CA
HRMY icon

Claris Advisors’s Harmony Biosciences HRMY Stock Holding History

Claris Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$80 – 547
2024
Q3 		$80 Buy
+2
New +$70 ﹤0.01% 1159

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Claris Advisors's HRMY Position: Q4 2024 in Review

Claris Advisors sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 2 shares — an estimated $80 sold.

Claris Advisors first reported a position in HRMY in Q3 2024 and held it in 1 quarter. The position peaked at $80 in Q3 2024. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

  • Claris Advisors reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 2 Harmony Biosciences shares in Q4 2024, an estimated $80.
  • Claris Advisors first reported a position in Harmony Biosciences in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Harmony Biosciences position peaked at $80 in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.